I have high risk smoldering and have held steady for the last year. My hematologist is a well known specialist. I have all the high risk chromosomal abnormalities, except for 17p. He wanted me to know that Mayo would most likely treat me now. He tends to not treat too early and then to treat aggressively with tandem SCT. I have been to Mayo and want to stay with this doctor. He did say that I will be a good candidate for Immunomodulating Therapy and that there are some being FDA hopefully in a year. I can not find any links with soon to be approved Immunotherapy agents. Any to be approved soon?
Thanks!
Forums
2 posts
• Page 1 of 1
-
Jaksix - Name: Jules
- Who do you know with myeloma?: Myself
- When were you/they diagnosed?: 2007 MGUS, 2012 Smoldering
- Age at diagnosis: 42
Re: Immunomodulating Therapy
I think you'll need to clarify with your hematologist exactly what he is talking about.
There are already 3 so-called "immunomodulatory agents" (sometimes called "imids") approved for the treatment of myeloma -- thalidomide, Revlimid, and Pomalyst. Also, Revlimid is being tested in a couple different trials as early treatment for high-risk myeloma patients.
It's possible that your hematologist means "immunotherapies", in which case he is probably referring to some of the so-called monoclonal antibodies ("mabs") being tested as potential myeloma drugs.
The monoclonal antibody that is furthest along in development for myeloma is elotuzumab. It may be approved in another year or two. There is a trial looking at its use in smoldering myeloma patients:
http://clinicaltrials.gov/ct2/show/NCT01441973
Another "mab" that is considered very promising is daratumumab, but I suspect it won't be approved by the FDA until after elotuzumab has been approved, and I don't know of any trials testing it in smoldering myeloma patients.
A third "mab" that is being looked at as a possible treatment for smoldering myeloma is siltuximab. Here is information about that trial:
http://clinicaltrials.gov/ct2/show/NCT01484275
There were some issues with siltuximab, however, when it was tested in patients with active (not smoldering) multiple myeloma.
There are already 3 so-called "immunomodulatory agents" (sometimes called "imids") approved for the treatment of myeloma -- thalidomide, Revlimid, and Pomalyst. Also, Revlimid is being tested in a couple different trials as early treatment for high-risk myeloma patients.
It's possible that your hematologist means "immunotherapies", in which case he is probably referring to some of the so-called monoclonal antibodies ("mabs") being tested as potential myeloma drugs.
The monoclonal antibody that is furthest along in development for myeloma is elotuzumab. It may be approved in another year or two. There is a trial looking at its use in smoldering myeloma patients:
http://clinicaltrials.gov/ct2/show/NCT01441973
Another "mab" that is considered very promising is daratumumab, but I suspect it won't be approved by the FDA until after elotuzumab has been approved, and I don't know of any trials testing it in smoldering myeloma patients.
A third "mab" that is being looked at as a possible treatment for smoldering myeloma is siltuximab. Here is information about that trial:
http://clinicaltrials.gov/ct2/show/NCT01484275
There were some issues with siltuximab, however, when it was tested in patients with active (not smoldering) multiple myeloma.
-
JimNY
2 posts
• Page 1 of 1
Return to Treatments & Side Effects